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ABSTRACT:   
 
Background: Hypertension is prevalent in chronic kidney disease (CKD). Studies 
suggest that reduction in dietary salt intake reduces blood pressure (BP). We studied 
relationships between salt intake, BP and renin angiotensin system regulation in 
order to establish if it is disordered in CKD. 
Methods: Mechanistic crossover study of CKD patients versus non-CKD controls. 
Participants underwent modified saline suppression test prior to randomisation to 
either low or high salt diet for 5 days and then crossed over to the alternate diet. 
Angiotensin-II stimulation testing was performed in both salt states. BP, urea and 
electrolytes, and plasma aldosterone concentration (PAC) were measured. 
Results: Twenty-seven subjects were recruited (12 CKD, 15 control). There was no 
difference in age and baseline BP between the groups. Following administration of 
intravenous saline, systolic BP increased in CKD but not controls (131 ± 16 mmHg to 
139 ± 14 mmHg, p=0.016, vs. 125 ± 20 mmHg to 128 ± 22 mmHg, p=0.38). Median 
PAC reduced from 184 (124,340) pmol/L to 95 (80,167) pmol in controls (p=0.003), 
but failed to suppress in CKD (230 (137,334) pmol to 222 (147,326) pmol (p=0.17)). 
Following dietary salt modification there was no change in BP in either group. Median 
PAC was lower following high salt compared to low salt diet in CKD and controls. 
There was a comparable increase in systolic BP in response to angiotensin-II in both 
groups. 
Discussion: We demonstrate dysregulation of aldosterone in CKD in response to salt 
loading with intravenous saline, but not to dietary salt modification.  
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Perspectives: 
 
1) This study was undertaken to explore aldosterone regulation and blood 
pressure response in patients with chronic kidney disease (CKD) under the 
influence of acute and chronic salt loading, in order to better understand the 
pathophysiology of hypertension in CKD. 
2) Our results show dysregulation of aldosterone in CKD in response to salt 
loading with intravenous saline, but not to dietary salt modification.  
3) Further research is required to explore the possible underlying mechanisms for 
the differential response to acute versus chronic salt loading in patients with 
CKD.  
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INTRODUCTION  
 
Patients with chronic kidney disease (CKD) are at an increased risk of end-stage 
renal disease (ESRD), cardiovascular disease (CVD) and death.(1,2) Hypertension, 
which is widely prevalent within CKD populations, is a modifiable risk factor for both 
CVD and progression of CKD.(3–6) The mechanism of hypertension in CKD is 
complex and incompletely understood. Over-activation of the renin-angiotensin-
aldosterone system (RAAS), in combination with salt and water retention, has been 
implicated.(7,8) Blockade of RAAS using medications which inhibit angiotensin 
activity has been shown to reduce the rate of CKD progression, reduce 
cardiovascular events and reduce proteinuria in patients with CKD, however many of 
these patients still progress to ESRD and die from CVD.(5,6)  
 
Aldosterone is accepted as having a detrimental effect in the pathogenesis of CVD, 
contributing to myocardial fibrosis and adverse cardiac modelling.(9) The 
phenomenon of “aldosterone breakthrough”, whereby excessive aldosterone activity 
occurs despite angiotensin inhibition, exists and predicts poor outcome.(7,10,11) The 
addition of drugs that block aldosterone activity at the mineralocorticoid receptor has 
established survival benefit in patients with congestive heart failure.(12,13) There is 
emerging evidence for the addition of these drugs for use in patients with CKD, with 
small trials showing reductions in proteinuria,(14) regression in left ventricular mass 
(LVM)(15) and potentially slowing the progression of CKD.(14,16,17)  
 
Dietary salt intake is an alternative potentially modifiable risk factor for hypertension 
and RAAS activation in CKD. The association between dietary salt and hypertension 
in the general population is well established, with studies showing up to a 25% 
reduction in CVD risk associated with a low salt diet.(18) In CKD populations, 
international guidelines(19) advise salt restriction, with some evidence to both 
support,(20–23) and refute,(24–26) this recommendation. Given these conflicting 
data, the association between dietary salt intake, RAAS activation and hypertension 
in CKD merits further study. Animal studies show that aldosterone induced organ 
damage in CKD is exacerbated in a high sodium environment, with acceleration of 
renal and cardiac fibrosis.(27,28) In humans, urinary sodium excretion, which is an 
established method of measuring dietary salt intake,(29,30) has been shown to be an 
inverse predictor of long-term survival in CKD and hypertensive patients,(31–33) and 
is also the main determinant of urinary corticosteroid excretion,(34) itself a predictor 
of LVM and proteinuria in CKD.(35)  
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The aim of this study is to explore aldosterone regulation and BP response in 
patients with CKD under the influence of acute and chronic salt loading, in order to 
better understand the pathophysiology of hypertension in CKD. We hypothesised 
that patients with CKD will fail to suppress aldosterone in response to acute and 
chronic salt loading. Furthermore, we hypothesised that salt-loaded CKD patients 
would be more susceptible to stimulation with angiotensin-II than non-CKD controls. 
 
METHODS AND MATERIALS 
Study design 
This was a mechanistic crossover study with subjects acting as their own control. 
Two groups of CKD and essential hypertension/control subjects were recruited. 
Details of each study visit are outlined in figure 1. All study visits were carried out in 
the Glasgow Cardiovascular Research Facility. To each study visit, subjects attended 
after a midnight fast with a completed 24-hour urine collection. To minimise the 
sequence effect subjects were divided in to two groups after visit one. Study visits 
two and three were identical to each other but were carried out after each 5-day 
dietary intervention. There was a two-week wash out period between dietary 
interventions. The study was approved by the West of Scotland ethics committee.  
 
Study population 
CKD subjects were recruited from the Western Infirmary (Glasgow) renal unit and its 
satellite general nephrology clinics. Hypertension subjects were recruited from the 
Western Infirmary Glasgow hypertension clinic. Control subjects were recruited by 
means of poster advertisement in the University of Glasgow. Exclusion criteria are 
listed in supplementary material table 1. 
 
Modified saline suppression test (visit 1) 
After 30 minutes of recumbent rest 1000 ml of 0.9% NaCl (3600 mg sodium) was 
infused over 2 hours with measurement of plasma aldosterone concentration (PAC) 
and plasma renin concentration (PRC) prior to and on completion of the infusion. 
Blood pressure (BP) and heart rate (HR) were recorded every 15 minutes throughout 
the infusion.  
 
Dietary salt manipulation 
Each diet was followed for 5 days prior to study visits 2 and 3. Subjects followed a 
diet sheet to achieve a low sodium intake of <2000 mg/day and were provided with 
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Slow Sodium® tablets (2 tablets twice daily, additional 920 mg sodium per day) to 
achieve a high sodium intake of >4600 mg/day.  
 
Angiotensin II stimulation test (visits 2 & 3) 
Angiotensin II acetate salt was obtained from BAChem Distribution Services, Weil 
am Rhein, Germany. After 30 minutes of recumbent rest, blood was obtained for 
measurement of PAC and PRC prior to and on completion of the infusion. BP and 
HR were measured every ten minutes during the infusion (60 minutes) and for a 
further 30 minutes following completion of the infusion. To minimise potential 
complications a graded dose infusion was used; 1.5 ng/kg/min for 30 minutes then 3 
ng/kg/min for a further 30 minutes.   
 
Sample analysis 
Measurement of PAC, PRC and urinary excretion of protein and electrolytes was 
carried out the Biochemistry laboratory, Western Infirmary, Glasgow. For PAC, 5 ml 
of blood was withdrawn in to an additive-free tube and spun at 3000 RPM for 10 
minutes at 4 0C. The plasma was stored at -80 0C. PAC was measured in batches 
utilising a radioimmunoassay (Siemens TKAL2). For PRC, 3.5 ml was withdrawn in 
to a potassium EDTA tube and then spun at 3000 RPM for 10 minutes at 4 0C. The 
plasma was stored at -80 0C. PRC was measured in batches using the DiaSorin 
Liason® analyzer.  
 
Outcomes 
The primary outcome measure was change in PAC in response to acute salt loading. 
Secondary outcomes included blood pressure and PAC response to dietary salt 
manipulation and angiotensin II infusion.   
 
Statistics and power calculation 
This was a study of a continuous response variable from matched pairs of study 
subjects. Previous data has shown PAC to reduce from 0.12 nmol/l to 0.07 nmol/l in 
response to a high salt diet in healthy volunteers.(36) In order to reject the null 
hypothesis (that CKD patients have a similar PAC response to acute salt loading) 
with 80% power and an alpha level of 0.05 a total of 24 subjects would be required, 
assuming a standard deviation of 0.05 nmol/l. Mean and standard deviation or 
median and interquartile range are reported for normally distributed and skewed 
results, respectively. Paired and independent t-tests were used, as appropriate, to 
compare normally distributed variables, with Wilcoxon signed rank tests being used 
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for comparative non-parametric variables. Repeated measures analysis of variance 
(ANOVA) was used to compare BP response to angiotensin-II between CKD and 
controls. All analysis were performed using SPSS 22.0 (IBM, NY) 
 
RESULTS 
Participants 
Twenty-seven subjects were recruited (12 CKD and 15 control). There was no 
significant difference in mean age, body-mass index (BMI), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), PAC or 24-hour urinary sodium (24-h USod) 
excretion at baseline between the groups (table 1). The CKD group had significantly 
lower estimated glomerular filtration rate (eGFR), higher serum potassium and higher 
PRC compared to the control group (table 1). Within the CKD group, primary renal 
diagnosis consisted of IgA nephropathy (7), granulomatosis with polyangiitis (2), 
reflux nephropathy (1), chronic pyelonephritis (1) and malignant hypertension (1). 
Nine patients in the CKD group were on medications that inhibit RAAS activity and 2 
patients were on a diuretic (1 loop, 1 thiazide) (supplementary material: table 2). The 
corresponding figures in the control group were 3 and 1 (thiazide), respectively.  
 
Modified saline suppression test (acute salt loading) 
Following administration of intravenous saline, there was a significant increase in 
mean SBP from baseline in the CKD group but not in the control group (table 2). 
Median PAC reduced in the control group, but failed to be suppressed in the CKD 
group (table 2).  PRC reduced in both groups in response to saline stimulation (table 
2). 
 
Modification of dietary salt intake (chronic salt loading) 
A significant difference in 24-h USod excretion was demonstrated following each 
dietary intervention in both groups (table 3). There was no significant difference in BP 
across the dietary interventions in either group (table 4). Median PAC was 
significantly lower following high dietary salt intake compared to low dietary salt 
intake in both patient groups (table 4). PRC was higher in the CKD group compared 
to control, but reduced in both groups in response to high dietary salt intake (table 4).   
Angiotensin-2 stimulation test 
SBP increased in response to angiotensin-2 in both groups on both diets 
(supplementary material: figure 1). There was no significant difference in SBP or 
DBP between controls and CKD in response to angiotensin-2 on either diet (2-way 
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repeated measures ANOVA: SBP low-salt diet p=0.184, SBP high salt diet p=0.242, 
DBP low salt p=0.239, DBP high salt diet p=0.498). In both groups on both diets, 
stimulation with angiotensin-2 increased PAC, while reducing median PRC (figure 2). 
Compared to a low salt diet, a high salt diet suppressed median PAC before and 
after angiotensin-2 administration in both groups (figure 2). There was no significant 
difference in PAC between control patients and those with CKD on either diet 
(p=0.09, p=0.15, p=0.48, and p=0.24 for CKD versus controls on low salt diet pre and 
post angiotensin II and high salt diet pre and post angiotensin II respectively). PRC 
was significantly higher in CKD patients than controls before and after angiotensin-2 
administration, however the relative change in PRC in response to angiotensin-2 
were similar in both groups.  
 
DISCUSSION 
The results of this study depict a complex, non-uniform response of RAAS activation 
following salt loading in patients with CKD (table 5). Firstly, we confirm that there is 
dysregulation of RAAS activation and BP response in patients with CKD following an 
acute salt and water load, with a rise in BP and failure to suppress PAC seen in the 
CKD group, but not controls, following a modified saline suppression test. Secondly, 
contrary to our hypothesis, a normal physiological response in aldosterone secretion, 
is maintained in CKD patients in response to dietary modification of salt intake. 
Finally, we show a comparable response in BP and PAC in response to angiotensin-
II stimulation in controls and CKD patients, even in a salt-loaded state.  
 
Previous randomised controlled trials have shown a reduction in BP following dietary 
salt restriction in patients with CKD.(20,21) However, controversy regarding the role 
of sodium restriction still exists due to a lack of survival benefit detected on 
observational data, with some signal that salt restriction may even increase 
mortality.(24–26,32,37,38) Given the overwhelming evidence for a detrimental role of 
aldosterone in CVD,(12,13,39) specifically in CKD patients,(15,40) the finding that 
PAC is suppressed in response to a high salt diet in both controls and CKD patients 
is difficult to reconcile with advice regarding salt restriction. This leaves the question 
as to how reduced dietary salt intake might reduce BP if it is not via aldosterone 
suppression. The possibility of direct salt and water retention resulting from reduced 
renal tubular excretion of sodium in CKD exists, but in line with previous studies, we 
did not find evidence of this when measured on 24-h USod.(30) Recent data 
suggesting that the kidney is not the only organ involved in sodium homeostasis (with 
large amounts of sodium sequestered in skin) and that sodium excretion is not strictly 
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diurnal would account for discrepancy between immediate sodium status, blood 
pressure and relative change in 24-h USod.(41) Furthermore, our results still support 
the hypothesis that aldosterone homeostasis is dysregulated in CKD, albeit not in 
response to modification of dietary salt intake.  
 
The observed differential response in CKD patients following acute versus chronic 
salt loading appears to be mediated by renin-independent aldosterone secretion.  In 
the setting of chronic dietary salt loading, there is a reduction in PRC that results in 
reduced PAC in both CKD and controls. However, in the acute setting this process is 
uncoupled in CKD patients. Potential mechanisms underpinning this difference 
include: i) renin-independent PAC secretion regulated by volume, not salt ii) 
dopaminergic renin-independent aldosterone regulation, with enhanced tubular 
dopamine excretion inhibiting PAC in CKD patients in the chronic setting, but not in 
the acute setting(42,43) iii) delayed aldosterone inhibition in CKD, with compensatory 
regulation of pro-renin receptors in chronic salt loading for which there is insufficient 
time to occur in the acute setting (44). There was no difference in serum potassium 
between the acute and chronic settings to explain the difference. Further research is 
required to explore the mechanisms behind the differential aldosterone response 
following acute and chronic salt loading in CKD patients, with monitoring of 
aldosterone activity following prolonged dietary intervention, measurement of urinary 
L-DOPA excretion and the addition of body-composition monitoring to inform 
regarding changes to extracellular fluid volume. 
 
Previous studies have suggested CKD is a particularly salt-sensitive state and salt 
restriction may augment the benefits of RAAS blockade.(23,45–48) Our results 
suggest that any adjuvant effect of salt restriction in combination with RAAS inhibition 
occurs in spite of higher, not lower, aldosterone levels, implying that by paradoxically 
stimulating RAAS activation with a low salt diet, it is possible to yield enhanced 
therapeutic effects from RAAS inhibiting medications. Furthermore, the lack of 
difference in response to angiotensin-II stimulation between controls and CKD 
patients even when on a high salt diet, contradicts the theory that a high salt state 
primes CKD patients to be particularly susceptible to angiotensin-II. Similar findings 
have been shown in normal subjects in whom adrenocorticotrophic hormone therapy 
resulted in hypertension even in a salt-depleted state.(49,50) PRC was significantly 
higher in CKD patients than controls at all stages, however this difference is likely to 
be explained by the differing prevalence RAAS inhibiting medications between the 
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groups.(51) PRC was higher in control patients receiving RAAS inhibiting 
medications compared to those who were not (data not shown). 
 
Strengths of this study include its crossover design and variety of relevant 
experimental conditions (acute salt loading, chronic salt loading, response to 
angiotensin-II stimulation). The results of this study are limited by small sample size: 
although adequately powered by our calculations, we cannot exclude the possibility 
of a smaller treatment effect being present but not detected. We acknowledge the 
confounding influence of including patients on RAAS inhibiting medications. As these 
drugs are fundamental in CKD standard of care, our results maintain generalisability, 
albeit potentially at the expense of data purity. Study of the effect of salt manipulation 
in CKD independent of use of RAAS inhibition would be required to address this 
confounding issue, but cessation of RAAS inhibitors in patients with proteinuric renal 
disease could be considered unethical. Alternatively, recruiting patients with 
ubiquitous use of RAAS inhibition in both CKD and non-CKD groups may be 
informative, but more challenging to recruit to. Despite the discrepancy in the 
prevalence of RAAS inhibiting medications between the groups there was no 
difference in PAC at baseline, suggesting aldosterone breakthrough had occurred in 
treated subjects. Furthermore, the fact that PAC varied in response to dietary 
manipulation in both groups suggests that relative changes within subjects were still 
possible despite concurrent RAAS inhibiting medications. Importantly we excluded 
patients on mineralocorticoid receptor antagonists and beta-blockers, and only a total 
of 3 patients were receiving a diuretic during the study. Inclusion of patients with 
hypertension as control subjects allows valuable comparison between patients 
groups, but may mask any difference between CKD and healthy volunteers. The 
aetiology of CKD within our sample was heterogeneous and different sub-groups of 
CKD patients may respond differently. Our dietary interventions lasted 5 days each, 
and it is possible that longer intervention may yield different results. However, we are 
reassured by confirmation that 24-h USod excretion was altered in response to 
dietary modification, albeit within the limitations of this method.(52) While increasing 
24-h USod has been shown to associate with mortality,(32,33) recent data suggests 
24-h USod is insensitive at detecting significant variations in dietary sodium 
intake.(53) Sodium regulation may not follow strict diurnal regulation and varies over 
weeks with less dependence on daily sodium intake than previously thought.(52)  
 
CONCLUSIONS 
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The results of this study enhance our understanding of the pathophysiology of 
hypertension in CKD patients by confirming dysregulation of aldosterone in response 
to acute salt loading. However, the lack of difference in BP and PAC in response to 
dietary salt modification calls into question the role of salt restriction in patients with 
CKD, particularly having shown that low salt diet results in higher PAC in both control 
and CKD participants. While clinical guidance should not change on the basis of 
these results alone, further research is required to explore the increasingly complex 
interaction between RAAS activation, dietary salt intake and hypertension in patients 
with CKD.  
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TABLES 
Table 1. Baseline demographics 
  Control group 
(n=15) 
CKD group 
(n=12) 
p value 
Age (years) 49.6 (14) 56 (9) 0.2 
Body mass index (kg/m2) 26.4 (4) 27.8 (4) 0.4 
Creatinine (µmol/L) 72.8 (11) 188.3 (68) <0.001 
eGFR (ml/min/1.73m2) 96.8 (11) 36.8 (16) <0.001 
Serum K+ (mmol/L) 4.1(0.3) 4.5 (0.5) 0.01 
Cortisol (nmol/L) 287(81) 317 (109) 0.4 
24hr urinary sodium 
excretion (mmol/24hr) 
122.3(50) 150 (76) 0.3 
Plasma Aldosterone** 
(pmol/L) 
184 (124,340) 230 (137,334) 0.4 
Plasma Renin** 
Concentration (mlU/L) 
16 (10,26) 73 (23,127) 0.002 
Antihypertensive 
Medication 
4 participants 12 participants  
Mean (standard deviation). **Median (inter-quartile range) 
eGFR = estimated glomerular filtration rate 
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Table 2. Response to modified saline suppression test (acute salt loading) in control 
group and chronic kidney disease (CKD). Tests of significance are paired t-test, or 
Wilcoxon signed rank test (*), for before and after saline  
  CONTROL GROUP CKD GROUP 
PRE POST p 
value 
PRE POST p 
value 
Systolic blood 
pressure 
(mmHg) 
125 (20) 128 (22) 0.4 132 (16) 139 (14) 0.016 
Diastolic blood 
pressure 
(mmHg) 
83 (12) 84 (13) 0.8 86 (13) 88 (12) 0.4 
Heart rate (bpm) 62 (10) 57 (11) 0.01 67 (15) 67 (15) 1.0 
Plasma 
Aldosterone* 
(pmol/L) 
184 
(124,340) 
95 
(80,167) 
0.003 230 
(137,334) 
222 
(147,326) 
0.17 
Plasma Renin* 
Concentration 
(mlU/L) 
16 (10,27) 9 
(5.0,15) 
<0.001 73 
(23,127) 
51 
(17,125) 
0.021 
Mean (standard deviation). *Median (inter-quartile range). 
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Table 3. 24-hour urinary sodium excretion depending on dietary intervention for 
control group and those with chronic kidney disease (CKD). 
 
 Urinary sodium excretion 
(mmol/24 hours) 
Baseline Low Sodium High Sodium 
Control Group 98 (92,154) 80 (60,145) 179 (134,224) 
CKD Group 123 (98,210) 91 (69,120) 174 (114,220) 
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Table 4. Response to low dietary salt intake versus high dietary salt intake in control 
group and chronic kidney disease (CKD). Tests of significance are paired t-test, or 
Wilcoxon signed rank test (*), compared to baseline 
  CONTROL GROUP CKD GROUP 
LOW HIGH p 
value 
LOW HIGH p 
value 
Systolic blood 
pressure 
(mmHg) 
122 (19) 124 (20) 0.5 125 (12) 132 (12) 0.07 
Diastolic blood 
pressure 
(mmHg) 
79 (13) 82 (13) 0.2 82 (9) 86 (8) 0.1 
Heart rate 
(bpm) 
60 (12) 62 (13) 0.06 64 (12) 67 (13) 0.04 
Serum Na+ 
(mmol/L) 
139 (2.0) 139 (1.6) 0.3 139 (1.9) 140 (0.8) 0.2 
Serum K+ 
(mmol/L) 
4.2 (0.4) 4.1 (0.3) 0.5 4.7 (0.6) 4.6 (0.45) 0.7 
Plasma 
Aldosterone* 
(pmol/L) 
309 
(184,380) 
162 
(84,225) 
 
0.007 424 
(253,739) 
188   
(138, 257) 
0.012 
Plasma Renin* 
Concentration 
(mlU/L) 
23  
(17,34) 
15  
(6,27) 
0.005 90  
(37, 234) 
79 
(24,132) 
0.003 
Mean (standard deviation). *Median (inter-quartile range).  
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Table 5. Summary of relative blood pressure (BP), plasma aldosterone concentration 
(PAC) and plasma renin concentration (PRC) response to acute salt loading 
(modified saline suppression test), chronic modification of dietary salt intake and 
angiotensin II stimulation (both low and high salt diets) in controls versus chronic 
kidney disease (CKD).  
 
 CONTROL 
 
CKD 
Acute salt and water load BP → 
PRC ↓ 
PAC ↓ 
 
BP ↑ 
PRC ↓ 
PAC → 
 
Chronic salt - LOW BP → 
PRC ↑ 
PAC ↑ 
 
BP→ 
PRC ↑ 
PAC ↑ 
Chronic salt – HIGH BP → 
PRC ↓ 
PAC ↓ 
 
BP → 
PRC ↓ 
PAC ↓ 
 
Angiotensin II 
stimulation (both diets) 
BP ↑ 
PRC ↓ 
PAC ↑ 
 
BP ↑ 
PRC ↓ 
PAC ↑ 
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FIGURES  
Figure 1: Flow chart of study visits.  
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Figure 2. Box plot of plasma aldosterone concentration before and after an infusion 
of angiotensin 2 in control group and chronic kidney disease (CKD) on low salt (A) 
and high salt (B) diets.  
A) 
 
B) 
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Supplementary material: Table 1. Study exclusion criteria 
Exclusion criteria 
Age <18 years or >85 years 
Pregnancy/breast feeding 
Medication prescription: Aldosterone antagonist 
    Direct renin inhibitor 
    Corticosteroids  
(including those prescribed treatment in preceding 3 months) 
Medical History: Conns syndrome 
   Addisons disease 
   Cushings disease 
   Type 1 diabetes mellitus 
   Severe coronary artery disease 
   Left ventricular systolic dysfunction 
CKD group: Decline in eGFR >5 ml/min/1.73m2 in preceding 6-months 
  Uncontrolled BP (>160/90 mmHg) 
  Urinary PCR >300 mg/mmol 
Control group: Uncontrolled BP (>160/90 mmHg) 
  Urinary PCR >20 mg/mmol 
 
Abbreviations: eGFR = estimated glomerular filtration rate; BP = blood pressure; 
PCR = protein:creatinine ratio. 
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Supplementary material: Table 2. Full list of participant medications.  
 
Participant Control group  Participant CKD group 
 
1 Amlodipine, Ramipril, 
Salbutamol. 
1 Allopurinol, Amlodipine, 
Bendroflumethiazide, 
Ramipril . 
2 Amlodipine, Valsartan. 2 Allopurinol, Felodipine, 
Sodium Bicarbonate. 
3 Bendroflumethiazide, 
Nifedipine, Perindopril, 
Simvastatin. 
3 Allopurinol, Lisinopril, 
Pravastatin, Salbutamol.  
4 Natur Nuriatum 
(Homeopathy). 
4 Allopurinol, Ramipril.  
5 Ranitidine. 5 Allopurinol, Vitamin D, 
Ramipril.  
6 Ramipril, Simvastatin, 
Symbicort, Ventolin. 
6 Amlodipine, Atorvastatin.  
7 Symbicort. 7 Amlodipine, Doxazosin, 
Ramipril. 
8  8 Amlodipine, 
Hydroxychloroquine, 
Nefopam. 
9  9 Aspirin, Furosemide, 
Levothyroxine, 
Mycophenolate mofetil, 
Ramipril, Simvastatin. 
10  10 Candesartan, Hormone-
replacement therapy, 
Simvastatin, Sodium 
Bicarbonate. 
11  11 Ezetemibe, Lisinopril, 
Paroxetine. 
12  12 Felodipine, Quinine, 
Ramipril, Rinzolamide, 
Travoprost. 
13    
14    
15    
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Supplementary material: Figure 1 
Line graph comparing mean systolic blood pressure over time during the 
angiotensin-2 stimulation test in control group and those with chronic kidney disease 
(CKD) following low salt diet (A) and high salt diet (B).  
A) 
 
B) 
 
 
